Generic drug maker Mylan Inc. (MYL: Quote), Friday said its unit Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application or ANDA for the generic version of Abbvie Inc.'s (ABBV: Quote) cholesterol drug Tricor or Fenofibrate.
Mylan said that its unit Mylan Pharmaceuticals Inc. has shipped Fenofibrate Tablets, 48 mg and 145 mg. The drug is prescribed as an adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides and apolipoprotein B, and to increase high-density lipoprotein cholesterol in adult patients. Fenofibrate Tablets also are indicated for treatment of adult patients with severe hypertriglyceridemia or high blood levels of triglycerides.
Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org